Supplementary Figure S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Key Points
MAIN FINDING: Combining tifcemalimab and toripalimab shows promise in enhancing treatment for advanced lung cancer.
KEY EVIDENCE: Kaplan-Meier estimates indicate a significant duration of response for patients treated with the combination.
APPROACH: Phase I/II trial assessed efficacy and safety of the antibody therapies in previously treated lung cancer patients.
SIGNIFICANCE: This research suggests a potential new treatment paradigm for challenging lung cancer cases.
Abstract
Supplementary Figure 2. Kaplan-Meier estimation of DOR.
Supplementary Figure S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer | Synapse
Also Consider
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: